You just read:

Phase 2 Data Show Daratumumab Achieved Overall Response Rate as Single-Agent in Heavily Pre-Treated Multiple Myeloma Patients

News provided by

Janssen-Cilag International NV

02 Jun, 2015, 19:30 BST